Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

Management of Dolutegravir-Induced Hyperglycemia in HIV Patients

Monitoring and Detection

  • Routine fasting blood glucose measurements should be performed at 3-4 month intervals during the first year of treatment, according to the Centers for Disease Control and Prevention guidelines 3, 4
  • Be vigilant for warning signs of hyperglycemia (polydipsia, polyphagia, polyuria) and educate patients about these symptoms, as recommended by the American Diabetes Association 3, 5
  • Glucose tolerance tests are not recommended for routine screening (DIII recommendation), as stated by the National Institutes of Health 3, 6

Management Approach

  • For patients experiencing dolutegravir-induced hyperglycemia, the American College of Physicians recommends lifestyle modifications, exercise, and dietary interventions as first-line management while continuing the dolutegravir-based regimen, with oral hypoglycemic agents or insulin added if necessary for glycemic control 1, 2
  • Implement lifestyle interventions, including dietary modifications and regular exercise, as first-line management for new-onset hyperglycemia or diabetes, as recommended by the American Heart Association 1, 2
  • Continue dolutegravir-based regimen in the absence of severe diabetes (BIII recommendation), according to the Infectious Diseases Society of America 3, 7

Special Considerations

  • Pregnant women require closer monitoring of blood glucose levels due to pregnancy being an independent risk factor for impaired glucose tolerance, as stated by the American College of Obstetricians and Gynecologists 3, 6
  • Patients with pre-existing diabetes should have more intensive monitoring when starting dolutegravir, as recommended by the Endocrine Society 3, 5

Clinical Outcomes and Prognosis

  • The long-term reversibility of dolutegravir-induced hyperglycemia is not well established, according to the National Institutes of Health 3, 4

Risk Factors to Consider

  • Longer duration of HIV infection is a risk factor for dolutegravir-induced hyperglycemia, as reported by the Centers for Disease Control and Prevention 1, 2